Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to evaluate the effectiveness of methadone alone and in combination with SAB378 for the treatment of painful HIV-associated neuropathy.
Condition | Intervention | Phase |
---|---|---|
HIV-associated Neuropathy Polyneuropathy |
Drug: SAB378 Drug: methadone Drug: SAB placebo Drug: Methadone placebo |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
Official Title: | NARC 011: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Methadone and Combination of Methadone and SAB378 in HIV-associated Painful Peripheral Neuropathy |
- Efficacy of methadone alone versus methadone and SAB378 for treatment of HIV-associated neuropathy [ Time Frame: At the end of each 4-week treatment period ] [ Designated as safety issue: Yes ]
- Effect on quality of life, emotional functioning, cognitive functioning, safety [ Time Frame: At the end of each 4-week treatment period ] [ Designated as safety issue: Yes ]
Enrollment: | 0 |
Study Start Date: | April 2009 |
Study Completion Date: | January 2010 |
Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active Comparator: 1
methadone plus SAB placebo
|
Drug: methadone
Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
Drug: SAB placebo
an inactive substance
|
Experimental: 2
methadone plus active SAB
|
Drug: SAB378
SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
Other Name: SAB
Drug: methadone
Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
|
Placebo Comparator: 3
methadone placebo plus SAB placebo
|
Drug: SAB placebo
an inactive substance
Drug: Methadone placebo
Methadone placebo
|
Detailed Description:
Distal sensory polyneuropathy is the most common neurological complication of HIV disease and its treatment. To date no standard effective therapy has been identified.
In this study, scientists will evaluate the effectiveness of treating HIV-associated neuropathy with methadone alone and in combination with a novel cannabinoid SAB378. A cannabinoid is a molecule found only in the Cannabis plant. Cannabis and some cannabinoids are effective analgesics or pain relievers. The rationale for combination therapy is twofold: (1) medications with unique mechanisms of action may affect different aspects of neuropathic pain and (2) combination therapy may act synergistically—meaning the combined effect may be greater than the effect of each drug alone.
Approximately 84 participants will be enrolled in this double-blind, placebo-controlled, crossover study. Participants will be randomly assigned to three treatment groups—those receiving methadone and SAB378 placebo (an inactive substance), those receiving methadone and active SAB378, or those receiving methadone placebo and SAB378 placebo. All participants will be exposed to each of the 3 treatment groups during the study.
This trial is part of the Neurologic AIDS Research Consortium, an effective collaborative clinical study group dedicated to the study of HIV-associated neurological disease.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-1 infection
- HIV-associated neuropathy diagnosed by a neurologist
- Presence of at least a moderate pain score on the basis of completion of a baseline pain diary
- Stable antiretroviral regimen for at least 8 weeks prior to study entry.
- Hemoglobin ≥ 8.0 g/dL for males and ≥ 7.5 g/dL for females
Exclusion Criteria:
- Active AIDS-defining opportunistic infection within 45 days prior to study entry
- Renal insufficiency
- Chronic liver disease
- B12 deficiency
- Family history of hereditary neuropathy
- Discontinuation of dideoxynucleoside NRTI within 16 weeks prior to entry
- On neuroregenerative therapy
- Treatment with neurotoxic drugs within 120 days prior to entry
- Respiratory compromise
- Hypotension
- Active substance abuse or dependence
- History of alcohol-related complications within 6 months prior to screening
- Women of childbearing potential
United States, California | |
AIDS Research Alliance | |
Los Angeles, California, United States | |
University of California, San Diego | |
San Diego, California, United States, 92093 | |
University of California, San Francisco | |
San Francisco, California, United States, 94122 | |
Stanford University | |
Stanford, California, United States, 94305 | |
United States, Maryland | |
Johns Hopkins University | |
Baltimore, Maryland, United States, 21287 | |
United States, Missouri | |
Washington University | |
St. Louis, Missouri, United States, 63110 | |
United States, New York | |
Montefiore Medical Center | |
Bronx, New York, United States | |
University of New York Downstate Medical Center | |
Brooklyn, New York, United States, 11208 | |
Mount Sinai Medical Center | |
New York, New York, United States, 10029 | |
Weill Medical College of Cornell University | |
New York, New York, United States, 10065 | |
University of Rochester | |
Rochester, New York, United States, 14620 |
Principal Investigator: | David B. Clifford, MD | Professor of Neurology, Washington University |
No publications provided
Responsible Party: | David B. Clifford, MD, Professor of Neurology, Washington University, PI, Neurologic AIDS Research Consortium |
ClinicalTrials.gov Identifier: | NCT00723918 History of Changes |
Other Study ID Numbers: | U01NS32228_NARC011, NARC 011 |
Study First Received: | July 28, 2008 |
Last Updated: | January 11, 2011 |
Health Authority: | United States: Food and Drug Administration |
Keywords provided by Washington University School of Medicine:
HIV-associated neuropathy HIV AIDS cannabinoid |
Cannabis methadone distal sensory polyneuropathy polyneuropathy |
Additional relevant MeSH terms:
Peripheral Nervous System Diseases Polyneuropathies Demyelinating Diseases Nerve Compression Syndromes Neurologic Manifestations Neurotoxicity Syndromes Neuromuscular Diseases Nervous System Diseases Signs and Symptoms Poisoning Substance-Related Disorders Methadone |
Analgesics, Opioid Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Central Nervous System Depressants Antitussive Agents Respiratory System Agents Narcotics |
ClinicalTrials.gov processed this record on March 10, 2013